Physician profile
Adam Dore
NPI 1467688747
$328,255.57
in general payments reported to CMS, 2019-2025
23 companies · $130K in 2025
The $130K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $10K · 2021: $6,845 · 2022: $55K · 2023: $27K · 2024: $55K · 2025: $130K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $149K · Consulting Fee: $33K · Travel and Lodging: $18K · Food and Beverage: $12K · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $148,691.50 |
| Consulting Fee | $33,427.50 |
| Travel and Lodging | $17,531.23 |
| Food and Beverage | $12,391.73 |
| Education | $366.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $140,158.35 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $88,725.22 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $59,565.98 | 2019-2025 | |
| Ucb, INC. | $22,308.60 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $7,931.79 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,697.52 | 2020-2025 | Cyltezo |
| Amgen INC. | $1,683.34 | 2019-2025 | Otezla, Tavneos, Enbrel |
| Astrazeneca Pharmaceuticals LP | $1,255.52 | 2021-2025 | Saphnelo |
| Ucb Sa | $920.00 | 2025 | Bimzelx |
| Pfizer INC. | $722.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $556.29 | 2019-2025 | Benlysta, Nucala |
| Sobi, INC | $177.81 | 2022-2025 | |
| Lilly USA, LLC | $143.80 | 2022-2025 | Taltz |
| Aurinia Pharma U.S., INC. | $117.18 | 2023-2024 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $78.77 | 2022-2023 | Opsumit, Uptravi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $53.37 | 2023-2025 | Idacio |
| Genentech USA, INC. | $42.74 | 2022-2025 | Actemra |
| Ani Pharmaceuticals, INC. | $37.60 | 2024 | Purified Cortrophin Gel |
| Genzyme Corporation | $26.15 | 2023 | |
| Sandoz INC. | $18.39 | 2024 | Hyrimoz |
| Kiniksa Pharmaceuticals International, Plc | $17.91 | 2024 | Arcalyst |
| Horizon Therapeutics Plc | $12.39 | 2019 | |
| Janssen Scientific Affairs, LLC | $4.08 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Dore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.